Results of the largest NET Patient Quality of Life Survey
Results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life The International Neuroendocrine Cancer Alliance (INCA) and Novartis announced the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer. Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were
You must be logged in to post a comment.